QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Cardium Therapeutics, Inc. (CXM) Focuses On Its Wound Care Tissue Engineering Technology, Excellagen 0 comments
    Mar 8, 2013 5:44 PM | about stocks: CXM

    Nothing is more dangerous to a diabetic than developing skin or tissue ulcers which may, if left untreated, necessitate the amputation of a finger, a toe, or even an entire hand or foot.

    These ulcers, the result of advanced diabetes or certain neuropathic conditions - in which wounds were left untreated - appear as a result of slowed circulation to extremities, a condition associated with both types of diabetes (i.e., Type I, an auto-immune disease, and Type II, which exhibits as high levels of sugar in the blood).

    These ulcers result in almost 80,000 lower extremity amputations yearly in the U.S., most often among elderly diabetics who have already lost some degree of mobility. It is this cohort - the 55 to 64-year old group, and those over 85 - which Cardium's Excellagen aims to address with an eye to lowering the odds of amputation and raising the likelihood of cures.

    Excellagen, cleared by the U.S. Food and Drug Administration, or FDA, and packaged in individual syringes for doctors' ease of use, provides a collagen that acts as a noncellular biological modulator. This compound, which contains no cells and resembles a cytoplasm, is in fact a collagen gel - a naturally-produced substance derived from the skin, muscle, bones, and tendons of cattle or ruminants.

    In the hospital or clinic, Cardium's 2.6 percent (of total volume) collagen gel behaves as a stimulant to speed up the formation of granulation tissue in and around the wound for more rapid and greatly improved ulcer healing.

    Whether used for diabetic foot ulcers, pressure ulcers, venous ulcers, or surgical and other type wounds, Excellagen excels when professionally administered after standard debridement technologies, which aim to scrape away dead tissue to encourage the formation of blood cells and platelets essential to the release of endogenous growth factors. These factors have been shown elsewhere to support and extend the migration of surviving cells in vitro - a highly beneficial feature that Cardium's researchers incorporated into their high molecular weight fiber-based Type I bovine collagen gel (BCG).

    Administering Excellagen once per week, in the presence of blood cells and platelets which naturally encourage the production and deposition of platelet-derived growth factor, or PDGF, has proven to be superior wound-healing technology. In fact, Excellagen trials across a spectrum of skin and tissue injuries, and ulcers, have shown Cardium's product superior to some other wound care approaches, largely because Excellagen is capable of speeding up granular tissue growth.

    Cardium's product also shows exceptional promise in the dermatology marketplace, where its ability to stimulate skin repair in the aftermath of surgery for patients suffering from squamous and basal cell carcinomas (two forms of skin cancer) has been highly rewarding. Similar therapy has also resulted in tissue repair deep into the periosteum, a membrane that covers bones. Finally, research into directing endochondral bone formation after implantation, which requires a biocompatible material as a scaffold to support growth, may see Excellagen or similar compounds being used to heal bony material.

    In time, Cardium's Excellagen could even find use as a collagen-based formula for the topical administration of antibiotics, peptides, proteins, DNA, stem cells, molecules, and the like. Given its healing ability - a 173-percent increase over other standard-of-care therapies in a single week - expect to see Excellagen appearing in many yet-to-be-determined venues.

    For more information, visit CardiumTHX.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: CXM
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.